VPC
XENE icon

Vestal Point Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Vestal Point Capital’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$37.2M Buy
639,900
+39,900
+7% +$1.84M 1.04% 34
2025
Q4 		$26.9M Sell
600,000
-500,000
-45% -$21M 0.99% 33
2025
Q3 		$44.2M Sell
1,100,000
-900,000
-45% -$31.7M 2% 17
2025
Q2 		$62.6M Buy
2,000,000
+700,000
+54% +$22.8M 3.3% 7
2025
Q1 		$43.6M Buy
1,300,000
+490,000
+60% +$18.6M 3.11% 9
2024
Q4 		$31.8M Sell
810,000
-15,000
-2% -$620K 1.88% 21
2024
Q3 		$32.5M Buy
825,000
+300,000
+57% +$12.1M 2.56% 16
2024
Q2 		$20.5M Buy
525,000
+125,000
+31% +$5M 1.53% 24
2024
Q1 		$17.2M Buy
400,000
+225,000
+129% +$10.3M 1.42% 17
2023
Q4 		$8.06M Buy
+175,000
New +$6.18M 0.85% 29

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.47T AUM 27.86% 1-Year Est. Return